drugset / Trial / NCT03971734
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Phase 1
Terminated
7 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
enroll patients with histologically confirmed high-grade gliomas to evaluate the ability of regadenoson to transiently disrupt a relatively intact blood-brain barrier (BBB). determine the best dose of regadenoson to disrupt the BBB and allow for enhanced penetration of gadolinium during MRI.
Timeline
- Start
- 2019-12-06
- Primary completion
- 2022-04-30
- Completion
- 2023-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regadenoson | Diagnostic / imaging agent | 0.05 mg | — |
| Subject | Regadenoson | Diagnostic / imaging agent | 0.1 mg | — |
| Subject | Regadenoson | Diagnostic / imaging agent | 0.2 mg | — |
| Subject | Regadenoson | Diagnostic / imaging agent | 0.4 mg | — |
| Subject | Regadenoson | Diagnostic / imaging agent | 0.7 mg | — |
| Subject | Regadenoson | Diagnostic / imaging agent | 1 mg | — |
| Subject | Regadenoson | Diagnostic / imaging agent | 1.4 mg | — |